Phytochemicals for Bacterial Resistance - Strengths, Weaknesses and Opportunities

 

 Permissions and Reprints

Abstract

This review covers some of the opportunities which currently exist to exploit plants for their natural products as templates for new antibacterial substances. This is a timely exercise given the continuing and developing problems of bacterial resistance, and in particular multidrug-resistance (MDR). Some of the challenges which are evident with bacterial resistance will be described and the strengths and weaknesses of plant natural products are highlighted. Opportunities to characterise antibacterial compounds from several key taxa are described with activity against methicillin-resistant Staphylococcus aureus (MRSA), MDR variants of this species and Mycobacterium tuberculosis (MTB). These pathogens continue to cause problems in terms of their eradication and spread and MTB strains which are extremely-drug resistant (XDR) promise to afford an additional challenge for clinicians. The review also covers plant natural products that modulate or modify bacterial resistance. Specific examples include plant-derived efflux pump inhibitors (EPIs) which inhibit bacterial antibiotic efflux mechanisms that are problematic due to their broadness in substrate specificity. A summary on future trends and directions in this fruitful and interesting area is also given.

References

• 1 Jevons M P. ’Celbenin’-resistant staphylococci.  Brit Med J. 1961;  1 124-5
  PubMedGoogle Scholar
• 2 Yee-Guardino S, Kumar D, Abughali N, Tuohy M, Hall G S, Kumar M L. Recognition and treatment of neonatal community-associated MRSA pneumonia and bacteremia.  Pediatr Pulmonol. 2008;  43 203-5
  CrossrefPubMedGoogle Scholar
• 3 Millar B C, Prendergast B D, Moore J E. Community-associated MRSA (CA-MRSA): an emerging pathogen in infective endocarditis.  J Antimicrob Chemother. 2008;  61 1-7
  CrossrefPubMedGoogle Scholar
• 4 O′Hara D M, Reynolds P E. Antibody used to identify penicillin-binding protein 2′ in methicillin-resistant strains of Staphylococcus aureus (MRSA).  FEBS Lett. 1987;  212 237-41
  CrossrefPubMedGoogle Scholar
• 5 Moult J, Sawyer L, Herzberg O, Jones C L, Coulson A F, Green D W. et al . The crystal structure of beta-lactamase from Staphylococcus aureus at 0.5 nm resolution.  Biochem J. 1985;  225 167-76
  PubMedGoogle Scholar
• 6 Hiramatsu K, Aritaka N, Hanaki H, Kawasaki S, Hosoda Y, Hori S. et al . Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin.  Lancet. 1997;  350 1670-3
  CrossrefPubMedGoogle Scholar
• 7 CDC. Staphylococcus aureus resistant to vancomycin - United States. Morbid Mortal Weekly Rep 2002 51: 565-7
  Google Scholar
• 8 Hentschke M, Saager B, Horstkotte M A, Scherpe S, Wolters M, Kabisch H. et al . Emergence of linezolid resistance in a methicillin resistant Staphylococcus aureus strain.  Infection. 2008;  36 85-7
  CrossrefPubMedGoogle Scholar
• 9 Bennett J W, Murray C K, Holmes R L, Patterson J E, Jorgensen J H. Diminished vancomycin and daptomycin susceptibility during prolonged bacteremia with methicillin-resistant Staphylococcus aureus. Diagn Microbiol Infect Dis 2007, in press
  Google Scholar
• 10 Karanika M, Prati A, Kiritsi M, Spiliopoulou I, Neonakis I, Anifantaki M. et al . Reduced susceptibility to quinupristin/dalfopristin in Enterococcus faecium in Greece without prior exposure to the agent.  Int J Antimicrob Agents. 2008;  31 55-7
  CrossrefPubMedGoogle Scholar
• 11 Office for National Statistics. Deaths involving MRSA and Clostridium difficile continue to rise. Health Statistics Quarterly 22 February 2007: 1-3
  Google Scholar
• 12 WHO Fact Sheet N^o 104. 2007 (http://www.who.int/mediacentre/factsheets/fs104/en/)
  Google Scholar
• 13 Goldman R C, Plumley K V, Laughon B E. The evolution of extensively drug resistant tuberculosis (XDR-TB): history, status and issues for global control.  Infect Disord Drug Targets. 2007;  7 73-91
  CrossrefPubMedGoogle Scholar
• 14 WHO. Extensively drug-resistant tuberculosis (XDR.TB): recommendations for prevention and control.  Weekly Epidemiol Record. 2006;  81 430-2
  PubMedGoogle Scholar
• 15 The tuberculosis X factor. Lancet Infect Dis 2006 6: 679
  Google Scholar
• 16 Magassouba F B, Diallo A, Kouyaté M, Mara F, Mara O, Bangoura O. et al . Ethnobotanical survey and antibacterial activity of some plants used in Guinean traditional medicine.  J Ethnopharmacol. 2007;  114 44-53
  CrossrefPubMedGoogle Scholar
• 17 Dupont S, Caffin N, Bhandari B, Dykes G A. In vitro antibacterial activity of Australian native herb extracts against food-related bacteria.  Food Control. 2006;  17 929-32
  CrossrefPubMedGoogle Scholar
• 18 Tasdemir D, Topaloglu B, Perozzo R, Brun R, O′Neill R, Carballeira N M. et al . Marine natural products from the Turkish sponge Agelas oroides that inhibit the enoyl reductases from Plasmodium falciparum, Mycobacterium tuberculosis and Escherichia coli. .  Bioorg Med Chem. 2007;  15 6834-45
  CrossrefPubMedGoogle Scholar
• 19 Available at http://www.chem.cornell.edu/jn96/outreach.html. Accessed 2007
  Google Scholar
• 20 Gibbons S. Anti-staphylococcal plant natural products.  Nat Prod Rep. 2004;  21 263-77
  CrossrefPubMedGoogle Scholar
• 21 Ciofalo M, Petruso S, Schillaci D. Quantitative assay of photoinduced antibiotic activities of naturally-occurring 2,2′:5′,2”-terthiophenes.  Planta Med. 1996;  62 374-5
  Article in Thieme ConnectPubMedGoogle Scholar
• 22 Gurevich A I, Dobrynin V N, Kolosov M N, Popravko S A, Riabova I D. Antibiotic hyperforin from Hypericum perforatum L.  Antibiotiki. 1971;  16 510-3
  PubMedGoogle Scholar
• 23 Schempp C M, Pelz K, Wittmer A, Schöpf E, Simon J C. Antibacterial activity of hyperforin from St John′s wort, against multiresistant Staphylococcus aureus and gram-positive bacteria.  Lancet. 1999;  353 2129
  PubMedGoogle Scholar
• 24 Lechner D, Stavri M, Oluwatuyi M, Pereda-Miranda R, Gibbons S. The anti-staphylococcal activity of Angelica dahurica (Bai Zhi).  Phytochemistry. 2004;  65 331-5
  CrossrefPubMedGoogle Scholar
• 25 Stavri M, Ford C H, Bucar F, Streit B, Hall M L, Williamson R T. et al . Bioactive constituents of Artemisia monosperma. .  Phytochemistry. 2005;  66 233-9
  CrossrefPubMedGoogle Scholar
• 26 Adams M, Wube A A, Bucar F, Bauer R, Kunert O, Haslinger E. Quinolone alkaloids from Evodia rutaecarpa: a potent new group of antimycobacterial compounds.  Int J Antimicrob Agents. 2005;  26 262-4
  PubMedGoogle Scholar
• 27 Adams M, Bauer R, Bucar F, Wube A A. Pharmaceutical preparation for treating mycobacterial infections with 4-quinolines from Evodia rutaecarpa. PCT Int Appl WO 2 006 094 327 2006
  Google Scholar
• 28 Rüegg T,  C alderónAI, Queiroz E F,  S olísPN,  M arstonA,  R ivasF. et al . 3-Farnesyl-2-hydroxybenzoic acid is a new anti-Helicobacter pylori compound from Piper multiplinervium. .  J Ethnopharmacol. 2006;  103 461-7
  CrossrefPubMedGoogle Scholar
• 29 Li X Z, Nikaido H, Poole K. Role of mexA-mexB-oprM in antibiotic efflux in Pseudomonas aeruginosa. .  Antimicrob Agents Chemother. 1995;  39 1948-53
  PubMedGoogle Scholar
• 30 Rezanka T, Sigler K. Sinaicinone, a complex adamantanyl derivative from Hypericum sinaicum. .  Phytochemistry. 2007;  68 1272-6
  CrossrefPubMedGoogle Scholar
• 31 Nagai M, Tada M. Antimicrobial compounds, chinesin I and II from flowers of Hypericum chinense L.  Chem Lett. 1987;  16 1337-40
  PubMedGoogle Scholar
• 32 Gibbons S, Ohlendorf B, Johnsen I. The genus Hypericum - a valuable resource of anti-Staphylococcal leads.  Fitoterapia. 2002;  73 300-4
  CrossrefPubMedGoogle Scholar
• 33 Gibbons S, Moser E, Hausmann S, Stavri M, Smith E, Clennett C. An anti-staphylococcal acylphloroglucinol from Hypericum foliosum. .  Phytochemistry. 2005;  66 1472-5
  CrossrefPubMedGoogle Scholar
• 34 Shiu W K, Gibbons S. Anti-staphylococcal acylphloroglucinols from Hypericum beanii. .  Phytochemistry. 2006;  67 2568-72
  CrossrefPubMedGoogle Scholar
• 35 Shiu W KP, Malkinson J P, Gibbons S. New antibacterial substances from Hypericum. UK Patent GB0718023.5 2007
  Google Scholar
• 36 Bolton S G, Null G, Troetel W M. The medical uses of garlic - fact and fiction.  J Am Pharm Assoc. 1982;  22 40-3
  PubMedGoogle Scholar
• 37 Cavallito C J, Buck J S, Suter C M. Allicin, the antibacterial principle of Allium sativum. I. Isolation, physical properties and antibacterial action.  J Am Chem Soc. 1944;  66 1950-1
  CrossrefPubMedGoogle Scholar
• 38 Healy F G, Wach M, Krasnoff S B, Gibson D M, Loria R. The txtAB genes of the plant pathogen Streptomyces acidiscabies encode a peptide synthetase required for phytotoxin thaxtomin A production and pathogenicity.  Mol Microbiol. 2000;  38 794-804
  CrossrefPubMedGoogle Scholar
• 39 Tims K J, Rathbone D L, Lambert P A, Attkins N, Cann S W, Billington D C. Mycobacterium fortuitum as a screening model for Mycobacterium tuberculosis. .  J Pharm Pharmacol. 2000;  52 135
  PubMedGoogle Scholar
• 40 O′Donnell G, Gibbons S. Antibacterial activity of two canthin-6-one alkaloids from Allium neapolitanum. .  Phytother Res. 2007;  21 653-7
  CrossrefPubMedGoogle Scholar
• 41 O′Donnell G, Bucar F, Gibbons S. Phytochemistry and antimycobacterial activity of Chlorophytum inornatum. .  Phytochemistry. 2006;  67 178-82
  CrossrefPubMedGoogle Scholar
• 42 Kaatz G W, Seo S M, Ruble C A. Efflux-mediated fluoroquinolone resistance in Staphylococcus aureus. .  Antimicrob Agents Chemother. 1993;  37 1086-94
  CrossrefPubMedGoogle Scholar
• 43 Colangeli R, Helb D, Sridharan S, Sun J, Varma-Basil M, Hazbón M H. et al . The Mycobacterium tuberculosis iniA gene is essential for activity of an efflux pump that confers drug tolerance to both isoniazid and ethambutol.  Mol Microbiol. 2005;  55 1829-40
  CrossrefPubMedGoogle Scholar
• 44 Marshall N J, Piddock L J. Antibacterial efflux systems.  Microbiologia. 1997;  13 285-300
  PubMedGoogle Scholar
• 45 Poole K, Srikumar R. Multidrug efflux in Pseudomonas aeruginosa: components, mechanisms and clinical significance.  Curr Top Med Chem. 2001;  1 59-71
  CrossrefPubMedGoogle Scholar
• 46 Poole K. Efflux mediated antimicrobial resistance.  J Antimicrob Chemother. 2005;  56 20-51
  CrossrefPubMedGoogle Scholar
• 47 Stermitz F R, Lorenz P, Tawara J N, Zenewicz L A, Lewis K. Synergy in a medicinal plant: antimicrobial action of berberine potentiated by 5′-methoxyhydnocarpin, a multidrug pump inhibitor.  Proc Natl Acad Sci U S A. 2000;  97 1433-7
  CrossrefPubMedGoogle Scholar
• 48 Morel C, Stermitz F R, Tegos G, Lewis K. Isoflavones as potentiators of antibacterial activity.  J Agric Food Chem. 2003;  51 5677-9
  CrossrefPubMedGoogle Scholar
• 49 Tegos G, Stermitz F R, Lomovskaya O, Lewis K. Multidrug pump inhibitors uncover remarkable activity of plant antimicrobials.  Antimicrob Agents Chemother. 2002;  46 3133-41
  CrossrefPubMedGoogle Scholar
• 50 Stavri M, Piddock L JV, Gibbons S. Bacterial efflux pump inhibitors from natural sources.  J Antimicrob Chemother. 2007;  59 1247-60
  CrossrefPubMedGoogle Scholar
• 51 Stermitz F R, Cashman K K, Halligan K M, Morel C, Tegos G P, Lewis K. Polyacylated neohesperidosides from Geranium caespitosum: bacterial multidrug resistance pump inhibitors.  Bioorg Med Chem Lett. 2003;  13 1915-8
  CrossrefPubMedGoogle Scholar
• 52 Gibbons S, Oluwatuyi M, Kaatz G W. A novel inhibitor of multidrug efflux pumps in Staphylococcus aureus. .  J Antimicrob Chemother. 2003;  51 13-7
  PubMedGoogle Scholar
• 53 Gibbons S, Kaatz G W. Unpublished results. 
  Google Scholar
• 54 Brunelli E, Minassi A, Appendino G, Moro L. 8-Prenylnaringenin, inhibits estrogen receptor-α mediated cell growth and induces apoptosis in MCF-7 breast cancer cells.  J Steroid Biochem. 2007;  107 140-8
  PubMedGoogle Scholar
• 55 Appendino G, Kaatz G W, Gibbons S. Unpublished results. 
  Google Scholar
• 56 Smith E CJ, Williamson E M, Kaatz G W, Gibbons S. Antibacterials and modulators from immature cones of Chamaecyparis lawsoniana. .  Phytochemistry. 2007;  68 210-7
  CrossrefPubMedGoogle Scholar
• 57 Nicolson K, Evans G, O’Toole P W. Potentiation of methicillin activity against methicillin-resistant Staphylococcus aureus by diterpenes.  FEMS Microbiol Lett. 1999;  179 233-9
  CrossrefPubMedGoogle Scholar
• 58 Jaiswal R, Beuria T K, Mohan R, Mahajan S K, Panda S. Totarol inhibits bacterial cytokinesis by perturbing the assembly dynamics of FtsZ.  Biochemistry. 2007;  46 4211-20
  CrossrefPubMedGoogle Scholar
• 59 Clarkson C, Musonda C C, Chibale K, Campbell W E, Smith P. Synthesis of totarol amino alcohol derivatives and their antiplasmodial activity and cytotoxicity.  Bioorg Med Chem. 2003;  11 4417-22
  CrossrefPubMedGoogle Scholar
• 60 Smith E CJ, Kaatz G W, Seo S M, Wareham N, Williamson E M, Gibbons S. The phenolic diterpene totarol inhibits multidrug efflux pump activity in Staphylococcus aureus. .  Antimicrob Agents Chemother. 2007;  51 4480-3
  CrossrefPubMedGoogle Scholar
• 61 Lechner D, Gibbons S, Bucar F. Modulation of isoniazid susceptibility by flavonoids in Mycobacterium. Phytochem Lett 2008, in press
  Google Scholar
• 62 Rahman M M, Garvey M, Piddock L JV, Gibbons S. Antibacterial terpenes from the oleo-resin of Commiphora molmol (Engl.). Phytother Res 2008, in press
  Google Scholar
• 63 Jones R N, Fritsche T R, Sader H S, Ross J E. Activity of retapamulin (SB-275 833), a novel pleuromutilin, against selected resistant Gram positive cocci.  Antimicrob Agents Chemother. 2006;  50 2583-6
  CrossrefPubMedGoogle Scholar

Simon Gibbons

Centre for Pharmacognosy and Phytotherapy

The School of Pharmacy

University of London

29-39 Brunswick Square

London WC1N 1AX

U.K.

Phone: +44-207-753-5913

Fax: +44-207-753-5909

Email: simon.gibbons@pharmacy.ac.uk